REGENXBIO

Historical price data

REGENXBIO is a publicly traded gene therapy leader built around its foundational NAV Technology Platform, comprising exclusive rights to over 100 novel AAV vectors, including the high-performing AAV8 and AAV9. The company's strategy combines advancing its own clinical pipeline, most notably in wet AMD with RGX-314, with a lucrative licensing model that includes partnerships with major biopharma companies like Novartis, Pfizer, and Takeda. With multiple clinical readouts expected in the near term and a strong financial position, REGENXBIO is positioned to be a key player in the next generation of gene therapies.

The NAV® Technology Platform is a proprietary adeno-associated virus (AAV) gene delivery platform comprising exclusive rights to over 100 novel AAV vectors, enabling targeted and efficient gene therapy for a wide range of diseases.

2 drugs in pipeline

REGENXBIO competes with other gene therapy developers in ophthalmology (e.g., Adverum) and rare diseases (e.g., Sarepta in DMD). Its primary competitive advantage is its foundational NAV Platform IP, which creates a durable moat and a unique dual-revenue model combining internal development with partner royalties.